Viatris Inc
NASDAQ:VTRS

Watchlist Manager
Viatris Inc Logo
Viatris Inc
NASDAQ:VTRS
Watchlist
Price: 11.61 USD -0.43% Market Closed
Market Cap: 13.4B USD

Intrinsic Value

The intrinsic value of one VTRS stock under the Base Case scenario is 31.61 USD. Compared to the current market price of 11.61 USD, Viatris Inc is Undervalued by 63%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

VTRS Intrinsic Value
31.61 USD
Undervaluation 63%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Viatris Inc

What is Valuation History?
Ask AI Assistant
What other research platforms think about VTRS?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is VTRS valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Viatris Inc.

Explain Valuation
Compare VTRS to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

Viatris continues to face margin compression on key legacy brands like Lipitor and EpiPen, as the company’s off-patent products encounter aggressive generic competition and price erosion worldwide.

The integration of Mylan and Upjohn has proved more complex than anticipated, creating ongoing restructuring costs and uncertainty that may delay anticipated synergy savings and limit near-term earnings growth.

High debt levels stemming from the merger could constrain the company’s ability to invest in new product pipelines, leaving Viatris trailing peers with more robust research and development spending.

Bull Theses

Viatris’s extensive global manufacturing and distribution footprint, inherited from both Mylan and Upjohn, creates economies of scale that could enhance the company’s competitiveness in emerging markets, boosting profitability in the long run.

The company’s diverse portfolio of off-patent brands and biosimilars, coupled with its pipeline expansion efforts, positions Viatris to capture market share as more biologics lose patent protection, offering new revenue streams.

Cost-savings initiatives from the merger, including divestitures of non-core assets, are on track to streamline operations further, potentially resulting in meaningful free cash flow growth and shareholder returns.

Show More Less
How do you feel about VTRS?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Viatris Inc

Current Assets 10B
Cash & Short-Term Investments 1.1B
Receivables 3.6B
Other Current Assets 5.3B
Non-Current Assets 28B
PP&E 2.9B
Intangibles 22.5B
Other Non-Current Assets 2.6B
Current Liabilities 7.4B
Accounts Payable 1.3B
Accrued Liabilities 2.6B
Other Current Liabilities 3.4B
Non-Current Liabilities 15.3B
Long-Term Debt 12.5B
Other Non-Current Liabilities 2.9B
Efficiency

Free Cash Flow Analysis
Viatris Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Viatris Inc

Revenue
14.1B USD
Cost of Revenue
-8.6B USD
Gross Profit
5.6B USD
Operating Expenses
-4.2B USD
Operating Income
1.3B USD
Other Expenses
-5B USD
Net Income
-3.7B USD
Fundamental Scores

VTRS Profitability Score
Profitability Due Diligence

Viatris Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.

Healthy Gross Margin
Sustainable 3Y Average Gross Margin
Sustainable 3Y Average Operating Margin
Low Operating Margin
37/100
Profitability
Score

Viatris Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.

VTRS Solvency Score
Solvency Due Diligence

Viatris Inc's solvency score is 32/100. The higher the solvency score, the more solvent the company is.

Long-Term Solvency
Low D/E
Short-Term Solvency
Positive Net Debt
32/100
Solvency
Score

Viatris Inc's solvency score is 32/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

VTRS Price Targets Summary
Viatris Inc

Wall Street analysts forecast VTRS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for VTRS is 12.38 USD with a low forecast of 9.09 USD and a high forecast of 15.75 USD.

Lowest
Price Target
9.09 USD
22% Downside
Average
Price Target
12.38 USD
7% Upside
Highest
Price Target
15.75 USD
36% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for VTRS is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

VTRS Insider Trading
Buy and sell transactions by insiders

VTRS News

Other Videos
What is the Intrinsic Value of one VTRS stock?

The intrinsic value of one VTRS stock under the Base Case scenario is 31.61 USD.

Is VTRS stock undervalued or overvalued?

Compared to the current market price of 11.61 USD, Viatris Inc is Undervalued by 63%.

Back to Top